6 completed, 1 active not recruiting, 1 enrolling by invitation, 1 recruiting. 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 6, Active not recruiting 1, Enrolling by invitation 1, Recruiting 1 |
Follow Epilepsy, Tonic-Clonic: new trials by email Literature Review of Epilepsy, Tonic-Clonic trials Research Report on Epilepsy, Tonic-Clonic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome Levetiracetam 500mg, Placebo - Down Syndrome, Down Syndrome (DS) | Phase 3 | Recruiting | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 120 | 2025-12-22 | 2026-01-12 |
| Clinical Trial of Vormatrigine in Adult Patients With Epilepsy vormatrogine - Epilepsy, Tonic-Clonic, Focal Seizure | Phase 3 | Enrolling by invitation | Praxis Precision Medicines | 700 | 2025-10-27 | 2026-08-03 |
| A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. Fenfluramine, Placebo - CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure | Phase 3 | Active not recruiting | Zogenix, Inc. | 87 | 2022-03-08 | 2026-04-29 |
| Monotherapy With Levetiracetam in Patients Suffering From Epilepsy. Levetiracetam - Epilepsy, Tonic-clonic | Phase 3 | Completed | UCB Pharma SA | 66 | 2005-08-10 | 2018-11-21 |
| Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures lamotrigine (LAMICTAL) extended-release, Placebo - Epilepsy, Tonic-Clonic | Phase 3 | Completed | GlaxoSmithKline | 153 | 2004-12-01 | 2017-01-02 |
| Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy. LEVETIRACETAM - Epilepsy, Tonic-clonic | Phase 3 | Completed | UCB Pharma | 250 | 2003-07-01 | 2013-11-26 |
| A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy topiramate - Epilepsy, Seizures | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 750 | 1999-07-01 | 2011-06-08 |
| A Study of the Efficacy and Safety of Topiramate in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures topiramate - Epilepsy, Seizures | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 80 | 1994-12-01 | 2011-06-08 |
| A Study of the Efficacy and Safety of Topiramate as "Add on" Treatment in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures topiramate - Epilepsy, Seizures | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 80 | 1994-03-01 | 2011-06-08 |
Epilepsy (8) · Seizures (7) · Alzheimer Disease (1) · CDKL5 deficiency disorder (1) · Dementia (1) · Down Syndrome (1) · Epilepsies, Partial (1) · Epilepsy, Generalized (1) · Spasms, Infantile (1)
Brain Diseases (9) · Central Nervous System Diseases (9) · Nervous System Diseases (9) · Epilepsy, Generalized (8) · Neurologic Manifestations (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Abnormalities, Multiple (1) · Chromosome Disorders (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Epilepsy (1) · Epileptic Syndromes (1) · Genetic Diseases, Inborn (1) · Intellectual Disability (1)
Levetiracetam (3) · Topiramate (3) · Fenfluramine (1) · Lamotrigine (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (3) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · GlaxoSmithKline (1) · Praxis Precision Medicines (1) · UCB Pharma (1) · UCB Pharma SA (1) · Zogenix, Inc. (1)
Germany (3) · Spain (3) · United States (3) · Brazil (2) · Italy (2) · Poland (2) · Argentina (1) · Austria (1) · Belgium (1) · Chile (1) · Czechia (1) · Georgia (1) · Hungary (1) · India (1) · Ireland (1)
PMID 10227614, PMID 10768306, PMID 17283312, PMID 20937567
2023 (1)